Currently, Lanier serves as the Lead Scientist of the National Tele-immersion Initiative, a coalition of research universities studying advanced applications for Internet 2. The Initiative demonstrated the first prototypes of tele-immersion in 2000 after a three year development period. His current tele-immersion-related research interests include real time, remote, terascale processing; autostereo methods; haptics; and software simulation component integration and reusability.
Patrick Lin, Ph.D. is the director of the Ethics + Emerging Sciences Group at California Polytechnic State University, San Luis Obispo. Currently, he is also a research fellow at the US Naval Academy, and he was previously a post-doctoral associate at Dartmouth College. Dr. Lin is known for his ethics work as related to nanotechnology, human enhancement, robotics, and other emerging technologies. For more information, please visit www.emergingethics.com.
David J. Linden, Ph.D., is a Professor in the Department of Neuroscience at the Johns Hopkins University School of Medicine. His laboratory has worked for many years on the cellular substrates of memory storage in the brain and a few other topics. You can see a list of some of his lab’s recent scientific papers here. He has a longstanding interest in scientific communication and serves as the… read more
Prof. Lloyd is interested in information and the role it plays in physical systems, particularly systems in the quantum regime. Specific questions are: How do physical systems register information and move it about? How is information transformed and processed? And, most importantly, how do the ways in… read more
Peter B. Lloyd graduated in mathematics at Cardiff University, Wales, where he stayed on to carry out research in solar engineering from 1981.
From 1987, he worked as a software developer in the ISIS medical research group in the University of Oxford. The ISIS group carried out what were, at the time, the largest clinical trials of medical interventions ever executed. With tens of thousands of patients recruited from intensive care units around the world, the trials were able to demonstrate the efficacy of emergency treatments for heart attacks such as streptokinase, a clot-dissolving drug that had previously been dismissed as too dangerous to use. And to demonstrate the lack of advantage of an expensive equivalent drug, tPA, derived from genetic engineering.… read more